🎙️ Interview with Serguei Melnik, Interim CEO and President of Nutriband Inc.
- nutribandcom
- 1 day ago
- 1 min read
In this exclusive interview, Serguei Melnik discusses the latest updates from Nutriband Inc., including the company’s core focus on combating the opioid crisis through its AVERSA™ abuse-deterrent transdermal technology.
Key topics covered:
Upcoming FDA meeting for AVERSA™ Fentanyl
Expansion of contract manufacturing through Pocono Pharmaceutical
Clinical development strategy with subsidiary 4P Therapeutics
Long-term vision and upcoming product pipeline
Commentary on recent financials and outlook
With only one Phase 1 trial required for AVERSA Fentanyl approval via the 505(b)(2) pathway, Nutriband’s innovative patch is well positioned to reshape opioid safety standards.
Learn more about Nutriband’s mission to reduce opioid abuse while improving patient care. Watch the full interview now and stay updated on Nutriband’s progress:
🔗 Full article from Wall Street Analyzer: